Approval Year
| Substance Class |
Protein
Created
by
admin
on
Edited
Fri Jun 25 20:34:14 UTC 2021
by
admin
on
Fri Jun 25 20:34:14 UTC 2021
|
| Protein Sub Type | |
| Sequence Type | COMPLETE |
| Record UNII |
7J9Y28299R
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
7J9Y28299R
Created by
admin on Fri Jun 25 20:34:14 UTC 2021 , Edited by admin on Fri Jun 25 20:34:14 UTC 2021
|
PRIMARY | |||
|
HER2/neu
Created by
admin on Fri Jun 25 20:34:14 UTC 2021 , Edited by admin on Fri Jun 25 20:34:14 UTC 2021
|
PRIMARY | |||
|
P04626
Created by
admin on Fri Jun 25 20:34:14 UTC 2021 , Edited by admin on Fri Jun 25 20:34:14 UTC 2021
|
PRIMARY |
| From | To |
|---|---|
| 1_4 | 1_31 |
| 1_140 | 1_170 |
| 1_173 | 1_182 |
| 1_177 | 1_190 |
| 1_198 | 1_205 |
| 1_202 | 1_213 |
| 1_214 | 1_222 |
| 1_218 | 1_230 |
| 1_233 | 1_242 |
| 1_246 | 1_273 |
| 1_277 | 1_289 |
| 1_293 | 1_309 |
| 1_312 | 1_316 |
| 1_320 | 1_345 |
| 1_453 | 1_482 |
| 1_489 | 1_498 |
| 1_493 | 1_506 |
| 1_509 | 1_518 |
| 1_522 | 1_538 |
| 1_541 | 1_554 |
| 1_545 | 1_562 |
| 1_565 | 1_574 |
| 1_578 | 1_601 |
| 1_604 | 1_612 |
| 1_608 | 1_620 |
| Glycosylation Type | HUMAN |
| Glycosylation Link Type | Site |
|---|---|
| N | 1_46 |
| N | 1_102 |
| N | 1_165 |
| N | 1_237 |
| N | 1_508 |
| N | 1_549 |
| N | 1_607 |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
INHIBITOR -> TARGET |
SELECTIVE
Ki
|
||
|
INHIBITOR -> TARGET | |||
|
|
INHIBITOR -> TARGET |
IgG1 bispecific antibody with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity targeting HER2 and HER3 receptors.
|
||
|
LIGAND->TARGET | |||
|
|
CONJUGATED TOXIN->TARGET | |||
|
|
INHIBITOR -> TARGET | |||
|
INHIBITOR -> TARGET | |||
|
|
RADIOLIGAND->TARGET | |||
|
INHIBITOR -> TARGET | |||
|
LIGAND->TARGET | |||
|
|
INHIBITOR -> TARGET | |||
|
CONJUGATED TOXIN->TARGET | |||
|
|
INHIBITOR -> TARGET | |||
|
|
LIGAND->TARGET | |||
|
INHIBITOR -> TARGET |
IC50
|
||
|
INHIBITOR -> TARGET |
IRREVERSIBLE INHIBITOR
IC50
|
||
|
ANTIGEN->TARGET |
Identified as a definitive diagnostic marker, key driver and therapeutic target for chordoma, a malignant tumor that arises from remnant notochordal cells lodged in the vertebrae
|
||
|
|
INHIBITOR -> TARGET | |||
|
|
CONJUGATED TOXIN->TARGET | |||
|
|
INHIBITOR -> TARGET | |||
|
INHIBITOR -> TARGET |
irreversible selective inhibitor
IRREVERSIBLE INHIBITOR
IC50
|
||
|
INHIBITOR -> TARGET | |||
|
|
INHIBITOR -> TARGET | |||
|
|
ANTIGEN->TARGET |
T-CELL ANTIGEN
|
||
|
|
CONJUGATED TOXIN->TARGET | |||
|
ANTIGEN->TARGET | |||
|
INHIBITOR -> TARGET |
HER dimerization inhibitor
BINDING
|
||
|
CONJUGATED TOXIN->TARGET | |||
|
|
INHIBITOR -> TARGET | |||
|
|
RADIOLIGAND->TARGET | |||
|
|
INHIBITOR -> TARGET | |||
|
ANTIGEN->TARGET | |||
|
|
INHIBITOR -> TARGET | |||
|
|
INHIBITOR -> TARGET | |||
|
|
INHIBITOR -> TARGET | |||
|
VACCINE ANTIGEN->TARGET | |||
|
|
INHIBITOR -> TARGET | |||
|
INHIBITOR -> TARGET |
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| Molecular Formula | CHEMICAL |
|
||||
| MOL_WEIGHT | CHEMICAL |
|